TOP NEWS

Emcure Pharma IPO: Focus Shifts to Allotment Date After Strong Subscription

Australian Premium

July 6, 2024

New Delhi, India

IPO Details

The Emcure Pharmaceuticals Limited IPO concluded with robust participation from investors. As the bidding ended on Friday, the focus now shifts to the allotment date and the grey market premium (GMP), which remains steady.

Emcure Pharma IPO Subscription Status

  • Total Subscription: The IPO was oversubscribed 67.87 times.
  • Retail Portion: Subscribed 7.21 times.
  • NII Portion: Subscribed 48.32 times.
  • QIB Segment: Subscribed 195.83 times.

The IPO received strong responses, particularly from Non-Institutional Investors (NII) and Qualified Institutional Buyers (QIB), indicating high investor confidence in Emcure Pharmaceuticals.

Emcure Pharma IPO GMP Today

  • Current GMP: ₹331, unchanged from Friday.
  • Market Sentiments: The steady GMP reflects positive sentiments in the Indian stock market and the strong subscription status of the IPO. Market observers believe the bullish trend may continue.

ALso Read: SEBI’s New F&O Rules Raise Costs for Stock Brokers

Key Dates for Emcure Pharma IPO

  • Allotment Date: Expected on Monday, July 8, 2024.
  • Listing Date: Expected on Wednesday, July 10, 2024.

How to Check Emcure Pharma IPO Allotment Status?

Once the share allocation is made public, bidders can check their allotment status online. Here’s how:

  1. BSE Website:
    • Go to the BSE website.
    • Navigate to the IPO allotment status page.
    • Enter the required details to check the status.

Also Read: Bansal Wire IPO Sees Strong Demand: Should You Apply?

Conclusion

The Emcure Pharma IPO has garnered significant attention and strong investor interest, as evidenced by its oversubscription. With the GMP holding steady and a bullish market outlook, all eyes are now on the allotment and listing dates. Investors are keenly awaiting the next steps to see how the stock performs upon listing.

IPO Watch

Stock Market Updates

Disclaimer:

CurrencyVeda provides this news article for informational purposes only. We do not offer investment advice or recommendations. Before making any investment decisions, please conduct thorough research, consult with financial experts, and carefully consider your financial situation, risk tolerance, and investment goals. Investing in the stock market carries risks, and it’s essential to make informed choices based on your individual circumstances. CurrencyVeda is not liable for any actions taken based on the information provided in this article.